[ad_1]
According to the news from Euronews CoronaVac vaccine, Chinese pharmaceutical company Sinovac Biotech and Brazilian biological researcher Bhutantan Institute ‘Developed in collaboration with.
Initial results in macaque monkeys revealed that the vaccine produces antibodies that neutralize 10 strains of Covid-19.
According to preliminary results of the first trials published in the Lancet, one of the world’s oldest medical journals, on November 17 the vaccine was found to be safe. However, it was claimed that the vaccine produced a moderate immune response with lower antibody levels compared to the patients who survived Kovid-19.
CoronaVac, Lancet’te, “An inactivated vaccine candidate against Kovid-19 that shows good immunogenicity in mice, rats and non-human primates” Is defined as.
When evaluating the vaccine, “We found that two doses of CoronaVac at different concentrations and with different dosing schedules were well tolerated and moderately immunogenic in healthy adults aged 18 to 59 years.” is called.
In addition to third-stage trials in people in Indonesia and Bangladesh, CoronaVac entered third-stage trials in Brazil in July.
The candidate vaccine experiments tested on 13,000 volunteers in Brazil were stopped on November 10 and restarted on November 12 due to an unexpected side effect.
[ad_2]
